This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-effectiveness analysis
Study objective
The objective was to assess the cost-effectiveness of ulipristal acetate as emergency contraception following unprotected sexual intercourse.
Interventions
The emergency hormonal contraceptive, ulipristal acetate 30mg, which was licensed for use up to 120 hours after unprotected sexual intercourse was compared with levonorgestrel 1.5mg. Levonorgestrel was licensed for use up to 72 hours after unprotected sexual intercourse and was the standard care in the UK at the time.
Location/setting
UK/primary care.
Methods

Analytical approach:
A decision-tree model was used to combine data from published studies. The time horizon was until abortion, miscarriage, or childbirth, for those who became pregnant despite treatment. The authors reported that the perspective of the NHS was adopted.
Effectiveness data:
The effectiveness estimates were from published studies. The efficacy of ulipristal acetate and levonorgestrel were from a meta-analysis of data from two UK clinical trials. The main measure of effectiveness was the probability of pregnancy.
Monetary benefit and utility valuations:
Not relevant.
Measure of benefit:
The measure of benefit was the pregnancy rate.
Cost data:
The economic analysis included the costs of the intervention (drugs and general practitioner consultation), the hospital costs of abortion or miscarriage, and the hospital and direct health care costs (including antenatal care) of childbirth. The unit costs and resource use data were from well-established sources, including the British National Formulary, the National Schedule of Reference Costs, and the National Institute for Health and Clinical Excellence (NICE). The price
